- Shionogi has increased its forecast for full-year operating income to 185 billion yen, higher than the previous estimate of 172.49 billion yen.
- The company expects net income for the fiscal year to be 188 billion yen, surpassing both previous projections of 180 billion yen and 180.04 billion yen.
- Forecasted net sales are lower than previous figures as it sees 500 billion yen, compared to the 530 billion yen it initially anticipated, although still similar to the earlier estimate of 506.57 billion yen.
- The company plans to maintain a dividend of 66 yen per share, consistent with estimates.
- In the second quarter, Shionogi’s operating income was 39.67 billion yen, down 17% year-over-year, and below the estimate of 42.68 billion yen.
- Second-quarter net income dropped by 16% year-over-year, ending at 44.19 billion yen, though it was slightly above the estimate of 43.68 billion yen.
- Net sales for the second quarter were 113.18 billion yen, showing a 2.7% decline year-over-year and falling short of the estimate of 115.41 billion yen.
- Current investor sentiment shows 4 buy ratings, 10 hold ratings, and 1 sell rating for Shionogi’s stock.
Shionogi & Co on Smartkarma
Analyst coverage of Shionogi & Co on Smartkarma by Tina Banerjee reveals a positive outlook on the company’s recent performance and future prospects. In the report titled “High on HIV Royalty; FY Guidance Reaffirmed; New Launches to Drive Growth,” for Q1FY26, Shionogi recorded a 2% revenue growth driven by its HIV franchise, with significant improvements compared to the previous year. Maintaining guidance for FY26 and progress in acquiring JT Group’s pharmaceutical business indicate a promising trajectory for the company.
Furthermore, Banerjee’s analysis in “Change Of Gears Likely From FY26, Torii Acquisition Augurs Well” highlights Shionogi’s revenue rise in FY25, propelled by royalties despite lower sales in infectious disease drugs. The acquisition of Torii Pharmaceutical and new drug submissions signal a shift towards product diversification and market opportunities in Japan, reinforcing the company’s growth strategy and market positioning.
A look at Shionogi & Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shionogi & Company Ltd., a pharmaceutical company, seems to have a positive long-term outlook based on its Smartkarma Smart Scores. With a score of 4 for Growth and Resilience, the company appears well-positioned to expand and adapt to market challenges. The moderate scores of 3 for both Value and Dividend indicate a balanced approach to financial performance and shareholder returns. Despite a lower Momentum score of 2, suggesting slower short-term price movement, Shionogi & Co‘s strong overall outlook bodes well for its future prospects in the pharmaceutical industry.
In summary, Shionogi & Co is a pharmaceutical company that focuses on developing prescription and over-the-counter drugs as well as diagnostics. Its Smartkarma Smart Scores reflect a promising future, with particularly high ratings in Growth and Resilience. While the company may not exhibit strong immediate market momentum, its strategic positioning in key areas signals potential for long-term success in the ever-evolving pharmaceutical landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
